EQS-Adhoc: QIAGEN N.V.: QIAGEN to propose initiation of annual cash dividend for shareholder approval at Annual General Meeting

07.05.25 14:35 Uhr

Werte in diesem Artikel
Aktien

37,44 EUR -0,49 EUR -1,28%

EQS-Ad-hoc: QIAGEN N.V. / Key word(s): Dividend
QIAGEN N.V.: QIAGEN to propose initiation of annual cash dividend for shareholder approval at Annual General Meeting

07-May-2025 / 14:35 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

Wer­bung


Ad hoc Announcement according to Art. 17 Market Abuse Regulation

QIAGEN to propose initiation of annual cash dividend for shareholder approval at Annual General Meeting

Venlo, the Netherlands, May 7, 2025 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announces that its Supervisory Board will propose the initiation of an annual cash dividend under an amended dividend policy to QIAGEN’s shareholders at the next Annual General Meeting scheduled for June 26, 2025.

This milestone reflects QIAGEN’s strategy to introduce a new avenue to increase shareholder returns while preserving flexibility to reinvest in long-term growth.

Wer­bung

The Supervisory Board’s decision on the amended dividend policy and initial dividend payment is subject to approval by QIAGEN’s shareholders.

The initial dividend payment would consist of $0.25 per ordinary share. This proposal represents a total payout of about $54 million. The record date is currently planned for July 2, 2025, and the payment date as July 10, 2025. All dates will be confirmed following shareholder approval.

Under the amended dividend policy, QIAGEN would have the ability to submit an annual dividend proposal to the Annual General Meeting that contemplates returning capital to shareholders while supporting sustainable growth and maintaining creditworthiness. The respective dividend proposal would consider various factors, including the amount of capital returned to shareholders, the availability of distributable profits and reserves, investments in production and R&D, working capital requirements, and potential M&A opportunities.

Wer­bung

 

 

QIAGEN N.V.

Hulsterweg 82

5912 PL Venlo

The Netherlands

 

ISIN: NL0015002CX3

Frankfurt Stock Exchange, Regulated Market (Prime Standard)

 


Contacts QIAGEN N.V.:

 

Corporate Communications

John Gilardi, Tel: +49 2103 29 11711; ir@qiagen.com

 



End of Inside Information

07-May-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: QIAGEN N.V.
Hulsterweg 82
5912 PL Venlo
Netherlands
Phone: +31 7735566 - 00
Fax: +31 77 35566-58
E-mail: qiagen@qiagen.com
Internet: www.qiagen.com
ISIN: NL0015002CX3
WKN: A40ZZU
Indices: DAX, TecDAX
Listed: Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; London, Chicago, NYSE, SIX
EQS News ID: 2132288

 
End of Announcement EQS News Service

2132288  07-May-2025 CET/CEST

Ausgewählte Hebelprodukte auf QIAGEN

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf QIAGEN

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Nachrichten zu QIAGEN N.V.

Wer­bung

Analysen zu QIAGEN N.V.

DatumRatingAnalyst
24.04.2025QIAGEN NeutralUBS AG
07.04.2025QIAGEN BuyDeutsche Bank AG
07.04.2025QIAGEN NeutralUBS AG
07.04.2025QIAGEN BuyJefferies & Company Inc.
28.03.2025QIAGEN BuyJefferies & Company Inc.
DatumRatingAnalyst
07.04.2025QIAGEN BuyDeutsche Bank AG
07.04.2025QIAGEN BuyJefferies & Company Inc.
28.03.2025QIAGEN BuyJefferies & Company Inc.
21.02.2025QIAGEN BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
14.02.2025QIAGEN BuyDeutsche Bank AG
DatumRatingAnalyst
24.04.2025QIAGEN NeutralUBS AG
07.04.2025QIAGEN NeutralUBS AG
06.02.2025Qiagen NV Registered NeutralUBS AG
20.11.2024QIAGEN HoldJefferies & Company Inc.
11.11.2024QIAGEN NeutralUBS AG
DatumRatingAnalyst
17.02.2021QIAGEN VerkaufenIndependent Research GmbH
14.12.2020QIAGEN VerkaufenDZ BANK
10.12.2020QIAGEN VerkaufenIndependent Research GmbH
24.11.2020QIAGEN VerkaufenIndependent Research GmbH
11.11.2020QIAGEN VerkaufenDZ BANK

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für QIAGEN N.V. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen